(Total Views: 661)
Posted On: 11/18/2019 4:51:58 AM
Post# of 145247
Second one I posted to ihub
$CYDY now 33c, June 2020 target $2 with first drug approval
Market share US only estimate for combo—-3 Billion Dollars
Company has raised over $200M to get the approval
Why leronlimab is superior? less side effects, weekly dosing, no resistance
$CYDY now 33c, June 2020 target $2 with first drug approval
![](http://investorshub.advfn.com/uimage/uploads/2019/11/18/mcukvcycytarget.jpg)
Market share US only estimate for combo—-3 Billion Dollars
![](http://investorshub.advfn.com/uimage/uploads/2019/11/18/px[jhmarket1.jpg)
![](http://investorshub.advfn.com/uimage/uploads/2019/11/18/sxytsmarketsize.jpg)
![](http://investorshub.advfn.com/uimage/uploads/2019/11/18/xxpximarketsize2.jpg)
Company has raised over $200M to get the approval
![](http://investorshub.advfn.com/uimage/uploads/2019/11/18/cbgbymoneyraised.jpg)
Why leronlimab is superior? less side effects, weekly dosing, no resistance
![](http://investorshub.advfn.com/uimage/uploads/2019/11/18/jtm[jwhybetter.jpg)
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)